PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
23635803-0	2013	ANKK1 and DRD2 pharmacogenetics of disulfiram treatment for cocaine abuse.	Disulfiram	35-45	ankyrin repeat and kinase domain containing 1	Homo sapiens	0-5	
23635803-2	2013	Since dopamine deficiency has been found with cocaine addiction, our objective was to examine whether functional variants in the ankyrin repeat and kinase domain-containing 1 (ANKK1) and/or the dopamine receptor D2 (DRD2) genes interact with response to treatment with disulfiram.	Disulfiram	269-279	ankyrin repeat and kinase domain containing 1	Homo sapiens	129-174	
23635803-6	2013	RESULTS: Patients with CT or TT ANKK1 genotypes dropped from 80 to 52% cocaine-positive urines on disulfiram (N=13; P<=0.0001), whereas those on placebo (N=20) showed no treatment effect.	Disulfiram	98-108	ankyrin repeat and kinase domain containing 1	Homo sapiens	32-37	
23635803-10	2013	CONCLUSION: A patient"s genotype for ANKK1, DRD2, or both, may be used to identify individuals for whom disulfiram may be an effective pharmacotherapy for cocaine dependence.	Disulfiram	104-114	ankyrin repeat and kinase domain containing 1	Homo sapiens	37-42